Jordan M. Schecter

10.3k total citations · 1 hit paper
104 papers, 2.5k citations indexed

About

Jordan M. Schecter is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jordan M. Schecter has authored 104 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Hematology, 66 papers in Oncology and 46 papers in Molecular Biology. Recurrent topics in Jordan M. Schecter's work include Multiple Myeloma Research and Treatments (79 papers), CAR-T cell therapy research (33 papers) and Protein Degradation and Inhibitors (33 papers). Jordan M. Schecter is often cited by papers focused on Multiple Myeloma Research and Treatments (79 papers), CAR-T cell therapy research (33 papers) and Protein Degradation and Inhibitors (33 papers). Jordan M. Schecter collaborates with scholars based in United States, Belgium and Germany. Jordan M. Schecter's co-authors include María‐Victoria Mateos, Xiang Qin, Katja Weisel, Tahamtan Ahmadi, Pieter Sonneveld, Ajay K. Nooka, William Deraedt, Andrew Spencer, Vânia Hungria and Himal Amin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jordan M. Schecter

100 papers receiving 2.4k citations

Hit Papers

Daratumumab, Bortezomib, and Dexamethasone for Multiple M... 2016 2026 2019 2022 2016 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    2016 1.1k citations Asher Chanan‐Khan, Katja Weisel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jordan M. Schecter United States 22 1.9k 1.5k 1.4k 326 306 104 2.5k
Andrew J. Yee United States 26 1.0k 0.6× 1.1k 0.7× 1.4k 1.0× 250 0.8× 230 0.8× 127 2.3k
J. Blake Bartlett United Kingdom 20 1.7k 0.9× 1.2k 0.8× 1.6k 1.1× 560 1.7× 552 1.8× 46 3.0k
Akil Merchant United States 24 818 0.4× 836 0.6× 1.5k 1.0× 226 0.7× 333 1.1× 84 2.5k
Antonella Gozzini Italy 22 1.0k 0.6× 408 0.3× 752 0.5× 533 1.6× 147 0.5× 75 1.7k
Anupriya Agarwal United States 28 1.7k 0.9× 497 0.3× 1.4k 1.0× 1.2k 3.6× 537 1.8× 85 3.1k
Maria Christina Cox Italy 30 1.2k 0.7× 842 0.6× 850 0.6× 516 1.6× 430 1.4× 111 2.8k
Andreas Hüttmann Germany 21 467 0.2× 523 0.4× 367 0.3× 449 1.4× 304 1.0× 66 1.7k
Olaf G. Wilhelm Germany 28 854 0.5× 741 0.5× 814 0.6× 280 0.9× 205 0.7× 61 2.4k
Daruka Mahadevan United States 24 693 0.4× 634 0.4× 834 0.6× 680 2.1× 410 1.3× 70 2.1k
Mark Brandt United States 28 2.0k 1.1× 616 0.4× 1.0k 0.7× 850 2.6× 190 0.6× 89 2.9k

Countries citing papers authored by Jordan M. Schecter

Since Specialization
Citations

This map shows the geographic impact of Jordan M. Schecter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordan M. Schecter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordan M. Schecter more than expected).

Fields of papers citing papers by Jordan M. Schecter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordan M. Schecter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordan M. Schecter. The network helps show where Jordan M. Schecter may publish in the future.

Co-authorship network of co-authors of Jordan M. Schecter

This figure shows the co-authorship network connecting the top 25 collaborators of Jordan M. Schecter. A scholar is included among the top collaborators of Jordan M. Schecter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordan M. Schecter. Jordan M. Schecter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arnulf, Bertrand, Tessa Kerre, Mounzer Agha, et al.. (2024). Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.. Journal of Clinical Oncology. 42(16_suppl). 7505–7505. 2 indexed citations
2.
Alsdorf, Winfried, Joris Diels, Francesca Ghilotti, et al.. (2024). Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of Comparative Effectiveness Research. 13(9). e240080–e240080. 3 indexed citations
3.
Dhakal, Binod, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Advances. 8(19). 5062–5071. 3 indexed citations
4.
Delforge, Michel, María‐Victoria Mateos, Kristina Carlson, et al.. (2024). Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma. Blood. 144(Supplement 1). 7085–7085. 3 indexed citations
5.
Yong, Kwee, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. European Journal of Cancer. 215. 115157–115157. 2 indexed citations
6.
Mateos, María‐Victoria, Katja Weisel, Joris Diels, et al.. (2023). Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study. Clinical Lymphoma Myeloma & Leukemia. 24(4). 224–231.e2.
7.
Crawford, Rebecca, Katharine S. Gries, Satish Valluri, et al.. (2022). The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies. Cancer Reports. 5(11). e1603–e1603. 7 indexed citations
8.
Marella, Mathieu, Xiang Yao, Vinicius Carreira, et al.. (2022). Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy. Journal of Histochemistry & Cytochemistry. 70(4). 273–287. 19 indexed citations
9.
Einsele, Hermann, Niels W.C.J. van de Donk, Bertrand Arnulf, et al.. (2021). CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S433–S434.
10.
Martin, Tom, Saad Z. Usmani, Jordan M. Schecter, et al.. (2021). Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion. 37(10). 1779–1788. 34 indexed citations
11.
12.
Cohen, Yaël C., Albert Oriol, Ka Lung Wu, et al.. (2020). Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(1). 46–54.e4. 12 indexed citations
13.
Soong, David, Jeran K. Stratford, Hervé Avet‐Loiseau, et al.. (2020). CNV Radar: an improved method for somatic copy number alteration characterization in oncology. BMC Bioinformatics. 21(1). 98–98. 11 indexed citations
14.
15.
16.
Lonial, Sagar, Jesús F. San Miguel, Joaquín Martínez‐López, et al.. (2017). Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study. Blood. 130. 1869–1869. 9 indexed citations
17.
18.
19.
Wu, Cheng–Chia, David P. Horowitz, Israel Deutsch, et al.. (2015). De-escalation of radiation dose for human papillomavirus-positive oropharyngeal head and neck squamous cell carcinoma: A case report and preclinical and clinical literature review. Oncology Letters. 11(1). 141–149. 4 indexed citations
20.
Lee, John C., Daniela Hoehn, Jordan M. Schecter, et al.. (2013). Lymphoid follicle colonization by Bcl-2bright+CD10+ B-cells (“follicular lymphoma in situ”) at nodal and extranodal sites can be a manifestation of follicular homing of lymphoma. Human Pathology. 44(7). 1328–1340. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew J. Yee Breakdown of academic impact, for papers by J. Blake Bartlett Breakdown of academic impact, for papers by Akil Merchant Breakdown of academic impact, for papers by Antonella Gozzini Breakdown of academic impact, for papers by Anupriya Agarwal Breakdown of academic impact, for papers by Maria Christina Cox Breakdown of academic impact, for papers by Andreas Hüttmann Breakdown of academic impact, for papers by Olaf G. Wilhelm Breakdown of academic impact, for papers by Daruka Mahadevan Breakdown of academic impact, for papers by Mark Brandt
Rankless by CCL
2026